N Frénoy

438 total citations
19 papers, 354 citations indexed

About

N Frénoy is a scholar working on Hematology, Pathology and Forensic Medicine and Oncology. According to data from OpenAlex, N Frénoy has authored 19 papers receiving a total of 354 indexed citations (citations by other indexed papers that have themselves been cited), including 7 papers in Hematology, 5 papers in Pathology and Forensic Medicine and 5 papers in Oncology. Recurrent topics in N Frénoy's work include Chronic Myeloid Leukemia Treatments (5 papers), Monoclonal and Polyclonal Antibodies Research (5 papers) and Lymphoma Diagnosis and Treatment (5 papers). N Frénoy is often cited by papers focused on Chronic Myeloid Leukemia Treatments (5 papers), Monoclonal and Polyclonal Antibodies Research (5 papers) and Lymphoma Diagnosis and Treatment (5 papers). N Frénoy collaborates with scholars based in France, Switzerland and United States. N Frénoy's co-authors include Brigitte Debuire, Sylvie Legrain, G. Neil Thomas, E E Baulieu, Claudine Berr, V. Gourlet, Etienne‐Emile Baulieu, P Burtin, A. Chabli and Emma Goldschmidt and has published in prestigious journals such as Journal of Clinical Oncology, The Journal of Immunology and The Journal of Clinical Endocrinology & Metabolism.

In The Last Decade

N Frénoy

17 papers receiving 337 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
N Frénoy France 10 145 83 63 46 45 19 354
Ann Hale United Kingdom 11 213 1.5× 75 0.9× 59 0.9× 15 0.3× 41 0.9× 17 515
Carol S. Hart United States 11 66 0.5× 27 0.3× 112 1.8× 7 0.2× 49 1.1× 17 410
Sabine Schröder Germany 13 157 1.1× 15 0.2× 99 1.6× 11 0.2× 43 1.0× 34 458
Elena Bianchi Italy 12 36 0.2× 11 0.1× 135 2.1× 33 0.7× 64 1.4× 27 419
Ljubica Bogić United States 12 41 0.3× 35 0.4× 149 2.4× 8 0.2× 16 0.4× 17 436
Jingjing Hu China 10 89 0.6× 9 0.1× 96 1.5× 18 0.4× 12 0.3× 36 326
M. Kremer United States 6 48 0.3× 13 0.2× 101 1.6× 9 0.2× 92 2.0× 11 315
T. D. Spector United Kingdom 9 71 0.5× 12 0.1× 39 0.6× 31 0.7× 25 0.6× 11 298
Fanny O’Brien United States 15 75 0.5× 4 0.0× 76 1.2× 100 2.2× 27 0.6× 24 818
Shen Sun China 9 143 1.0× 15 0.2× 109 1.7× 38 0.8× 28 0.6× 14 422

Countries citing papers authored by N Frénoy

Since Specialization
Citations

This map shows the geographic impact of N Frénoy's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by N Frénoy with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites N Frénoy more than expected).

Fields of papers citing papers by N Frénoy

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by N Frénoy. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by N Frénoy. The network helps show where N Frénoy may publish in the future.

Co-authorship network of co-authors of N Frénoy

This figure shows the co-authorship network connecting the top 25 collaborators of N Frénoy. A scholar is included among the top collaborators of N Frénoy based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with N Frénoy. N Frénoy is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

19 of 19 papers shown
1.
Machover, D., Béatrice Delmas-Marsalet, Ayhan Ulusakarya, et al.. (2009). Treatment with rituximab, dexamethasone, high-dose cytarabine, and oxaliplatin (R-DHAOx) produces a strong long-term antitumor effect in previously treated patients with follicular non-Hodgkin's lymphoma. Biomedicine & Pharmacotherapy. 64(2). 83–87. 5 indexed citations
2.
3.
4.
Machover, D., Béatrice Delmas-Marsalet, Emma Goldschmidt, et al.. (2001). Dexamethasone, high-dose cytarabine, and oxaliplatin (DHAOx) as salvage treatment for patients with initially refractory or relapsed non-Hodgkin’s lymphoma. Annals of Oncology. 12(10). 1439–1443. 37 indexed citations
5.
Saffroy, Raphaël, Antoinette Lemoine, N Frénoy, et al.. (2000). Real‐time quantitation of bcr‐abl transcripts in haematological malignancies. European Journal Of Haematology. 65(4). 258–266. 22 indexed citations
6.
Pham, Hung, Antoinette Lemoine, M Salvucci, et al.. (1998). Occurrence of gammopathies and lymphoproliferative disorders in liver transplant recipients randomized to tacrolimus (FK506)- or cyclosporine-based immunosuppression. Liver Transplantation and Surgery. 4(2). 146–151. 14 indexed citations
7.
Lin, Bryan, M Musset, J. Alexandre, et al.. (1997). Human T-cell lymphotropic virus-1-positive T-cell leukemia/lymphoma in a child. Report of a case and review of the literature.. PubMed. 121(12). 1282–6. 13 indexed citations
8.
Legrain, Sylvie, Claudine Berr, N Frénoy, et al.. (1995). Dehydroepiandrosterone Sulfate in a Long-term Care Aged Population. Gerontology. 41(6). 343–351. 72 indexed citations
9.
Frénoy, N, et al.. (1994). Application of a new protocol for nested PCR to the detection of minimal residual bcr/abl transcripts.. PubMed. 8(8). 1411–4. 8 indexed citations
10.
Thomas, G. Neil, et al.. (1994). Serum dehydroepiandrosterone sulfate levels as an individual marker.. The Journal of Clinical Endocrinology & Metabolism. 79(5). 1273–1276. 115 indexed citations
11.
Debuire, Brigitte, A. Chabli, & N Frénoy. (1993). Fast, manual, nonradioactive method for DNA sequencing.. PubMed. 39(8). 1682–5. 12 indexed citations
12.
Debuire, Brigitte, A. Chabli, & N Frénoy. (1993). Fast, manual, nonradioactive method for DNA sequencing. Clinical Chemistry. 39(8). 1682–1685. 10 indexed citations
13.
Frénoy, N, et al.. (1988). Natural antibodies against the carcinoembryonic antigen (CEA) and a related antigen, NCA, in human sera.. PubMed. 7(6). 1229–33. 17 indexed citations
14.
Burtin, P, G Chavanel, J.C. Hendrick, & N Frénoy. (1986). Antigenic variants of the nonspecific cross-reacting antigen (NCA).. The Journal of Immunology. 137(3). 839–845. 14 indexed citations
15.
Chavanel, G, et al.. (1983). Production of monoclonal antibodies against the non-specific cross-reacting antigen (NCA).. PubMed. 4(3). 209–17. 3 indexed citations
16.
Frénoy, N, et al.. (1982). An investigation of factors influencing serum NCA (non-specific cross-reacting antigen) level in patients with chronic myeloid leukaemia. British Journal of Cancer. 46(5). 765–772. 1 indexed citations
17.
Frénoy, N & P Burtin. (1980). Non-specific cross-reacting antigen serum concentration in myeloid leukemias. Clinica Chimica Acta. 103(1). 23–31. 5 indexed citations
18.
Frénoy, N, et al.. (1971). Préparation et caractérisation de la transferrine urinaire. Biochimie. 53(11-12). 1207–1212. 1 indexed citations
19.
Frénoy, N, et al.. (1971). Préparation de la transferrine du sérum humain. Clinica Chimica Acta. 32(2). 243–249. 5 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Ann Hale Breakdown of academic impact, for papers by Carol S. Hart Breakdown of academic impact, for papers by Sabine Schröder Breakdown of academic impact, for papers by Elena Bianchi Breakdown of academic impact, for papers by Ljubica Bogić Breakdown of academic impact, for papers by Jingjing Hu Breakdown of academic impact, for papers by M. Kremer Breakdown of academic impact, for papers by T. D. Spector Breakdown of academic impact, for papers by Fanny O’Brien Breakdown of academic impact, for papers by Shen Sun
Rankless by CCL
2026